ArticleFree radical biology & medicine2026
Mitsugumin 53 protects against smoke inhalation lung injury via suppressing the proinflammatory response in a rat model.
Article in Free radical biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MG53, a Regenerative Myokine Linking Skeletal Muscle to Cardiac Repair.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesThis study investigates the therapeutic potential of recombinant human Mitsugumin 53 (rhMG53) in a rodent model of smoke-induced acute lung injury (SI-ALI). We hypothesize that administration of rhMG53 will improve pulmonary function and attenuate inflammation following SI-ALI.
methodsSprague Dawley rats (n = 6-9/group, 300-400 g) underwent smoke inhalation or sham. Smoke-exposed rats received intravenous rhMG53 or saline. Arterial blood gases were obtained at baseline and 2, 6, and 24 h post smoke inhalation. Lung tissue collected at 24 h was analyzed via histopathology, immunofluorescence, bulk RNA sequencing, quantitative PCR, and western blotting.
resultsSix hours after smoke exposure, saline-treated rats exhibited dampened partial pressure of oxygen, whereas the rhMG53 group showed significant improvement (62.67 ± 15.81 vs. 75.83 ± 12.16 mmHg, P < .01). By 24 h, saline-treated animals remained significantly hypoxemic (79.33 mmHg, P < .01 vs. baseline), while rhMG53-treated rats recovered to baseline (87.17 mmHg), trending toward significantly higher oxygenation versus saline (P = 0.0503). Smoke-exposed saline-treated rats exhibited increased overall histopathological scores, which were reduced with rhMG53 (0.60 ± 0.17 vs. 0.37 ± 0.05, P < .01). Gene ontology analysis revealed rhMG53 mitigated smoke-induced upregulation of inflammatory response pathways. Induction of pro-inflammatory genes and elevation of NLRP3 inflammasome expression observed in smoke-exposed saline-treated lungs was significantly suppressed by rhMG53, as corroborated by qPCR and western blotting.
conclusionsThis study provides preclinical evidence for rhMG53 as a potential therapeutic for SI-ALI. RhMG53 improved oxygenation, reduced neutrophilic inflammation, and suppressed NLRP3 inflammasome activation. Further investigations in diverse models of ALI are warranted to define the therapeutic scope and translational potential of rhMG53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.